| 1.04 0.174 (20.08%) | 04-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.22  |
1-year : | 1.43 |
| Resists | First : | 1.04 |
Second : | 1.22 |
| Pivot price | 0.77 |
|||
| Supports | First : | 0.79 |
Second : | 0.63 |
| MAs | MA(5) : | 0.84 |
MA(20) : | 0.76 |
| MA(100) : | 0.81  |
MA(250) : | 0.94 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 85.2 |
D(3) : | 74.1 |
| RSI | RSI(14): 77.1 |
|||
| 52-week | High : | 1.69 | Low : | 0.46 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ LEXX ] has closed above the upper band by 31.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 14.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.05 - 1.06 | 1.06 - 1.06 |
| Low: | 0.87 - 0.87 | 0.87 - 0.88 |
| Close: | 1.03 - 1.04 | 1.04 - 1.05 |
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Thu, 02 Apr 2026
LEXX Technical Analysis & Stock Price Forecast - Intellectia AI
Wed, 01 Apr 2026
Lexaria Bioscience (LEXX) Launches Key Human Pilot Study - gurufocus.com
Wed, 01 Apr 2026
Lexaria to Begin New Human Clinical Study in GLP-1 - The Batesville Daily Guard
Wed, 01 Apr 2026
A 5-week human trial will test Lexaria's oral GLP-1 against Wegovy - Stock Titan
Sun, 22 Mar 2026
If You Invested $1,000 in Lexaria Bioscience Corp (LEXX) - Stock Titan
Wed, 18 Mar 2026
100,000 Lexaria (LEXX) shares gifted back to the company - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 2.354e+007 (%) |
| Held by Institutions | 5.7 (%) |
| Shares Short | 653 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.044e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 14.6 % |
| Return on Equity (ttm) | -83 % |
| Qtrly Rev. Growth | 522000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -277.2 |
| EBITDA (p.s.) | 932143 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 2.64 |
| Dividend | 0 |
| Forward Dividend | 373100 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|